ArticleJournal of thoracic disease2025

Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective study.

Xiaoqi Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.